Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | MicrobiomeTrials← Back to trialsNCT05327023
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-05-23Est. Completion: 2028-07-03
Enrollment target: 430 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Breast CancerBreast CarcinomaCancer of the BreastMalignant Neoplasm of Breast
Background:
Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or bra…
Bethesda, United StatesEst. completion Jul 1, 2033
LeukemiaLymphomaMultiple MyelomaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and…
Omaha, United StatesEst. completion Jul 2027